生长抑素与乌司他丁治疗炎性肠梗阻的临床疗效及安全性研究

Clinical efficacy and safety of single use of somatostatin combined with ulinastatin in the treatment of inflammatory ileus

目的观察联合生长抑素与乌司他丁治疗炎性肠梗阻的临床疗效及安全性。方法将46例炎性肠梗阻患者按随机数字表法分为对照组23例和试验组23例。对照组予以生长抑素每12h静脉泵入3mg,1周后逐渐停药;试验组在对照组的基础上,给予静脉滴注乌司他丁10万U,每日2次。用酶联免疫吸附试验(ELISA)检测血清中白细胞介素(IL)-6、IL-8和肿瘤坏死因子(TNF)-α表达水平。比较2组患者的临床疗效和不良反应发生率。结果治疗后,试验组的总有效率(91%)显著高于对照组(70%)(P<0.05)。治疗后,2组患者的IL-6、IL-8和TNF-α表达水平均明显低于治疗前(P<0.05),但治疗后试验组IL-6、IL-8和TNF-α表达水平低于对照组(P<0.05)。试验组的不良反应发生率(4%)低于对照组(22%)(P<0.05)。结论生长抑素联合乌司他丁治疗炎性肠梗阻的临床疗效确切,无明显不良反应。

Objective To observe the clinical efficacy and safety of somatostatin combined with ulinastatin in the treatment of inflammatory ileus.Methods Forty-six patients with inflammatory intestinal obstruction were divided into control group(n=23)and treatment group(n=23)by random number table method.The control group was treated with somatostatin intravenous infusion 3 mg·q12 h,gradual withdrawal after 1 week.Treatment group received intravenous infusion of ulinastatin 100 thousand U bid on the basis of the control group.The expression levels of serum interleukin(IL)-6,IL-8 and tumor necrosis factor(TNF)-αwere compared by enzyme linked immunosorbent assay(ELISA).The clinical efficacy and incidence of adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of the treatment group was significantly higher than that of control group(91%vs 70%,P<0.05),After treatment,the expression levels of IL-6,IL-8 and TNF-αwere significantly lower than those before treatment in two groups(P<0.05).But,after treatment the expression levels of IL-6,IL-8 and TNF-αin the treatment group were lower than those in the control group(P<0.05).The incidence of adverse reactions in treatment group was significantly lower than that of control group(4%vs 22%,P<0.05).Conclusion The clinical curative effect of somatostatin combined with ulinastatin in the treatment of inflammatory ileus is good,and there is no obvious adverse reaction.